The Knowledge Profile, Competence and Pending Problems of Chinese Anesthesiologists in Dealing with Malignant Hyperthermia: A Cross-Sectional Survey

References

• Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:93. doi:10.1186/s13023-015-0310-1
   PubMed Web of Science ®Google Scholar
• Broman M, Islander G, Müller CR. Malignant hyperthermia, a Scandinavian update. Acta Anaesthesiol Scand. 2015;59(8):951–961. doi:10.1111/aas.12541
   PubMed Web of Science ®Google Scholar
• Correia ACDC, Silva PCB, Silva BAD. Malignant hyperthermia: clinical and molecular aspects. Rev Bras Anestesiol. 2012;62(6):820–837. doi:10.1016/S0034-7094(12)70182-4
   PubMed Web of Science ®Google Scholar
• Litman RS, Smith VI, Larach MG, et al. Consensus statement of the malignant hyperthermia association of the United States on unresolved clinical questions concerning the management of patients with malignant hyperthermia. Anesth Analg. 2019;128(4):652–659. doi:10.1213/ANE.0000000000004039
   PubMed Web of Science ®Google Scholar
• Jones PM, Allen BN, Cherry RA, et al. Association between known or strongly suspected malignant hyperthermia susceptibility and postoperative outcomes: an observational population-based study. Can J Anesth. 2019;66(2):161–181. doi:10.1007/s12630-018-1250-8
   PubMed Web of Science ®Google Scholar
• Rüffert H, Bastian B, Bendixen D, et al. Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group. Br J Anaesth. 2021;126(1):120–130. doi:10.1016/j.bja.2020.09.029
   PubMed Web of Science ®Google Scholar
• Glahn KPE, Bendixen D, Girard T, et al. Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines. Br J Anaesth. 2020;125(2):133–140. doi:10.1016/j.bja.2020.04.089
   PubMed Web of Science ®Google Scholar
• Hopkins PM, Girard T, Dalay S, et al. Malignant hyperthermia 2020: guideline from the association of anaesthetists. Anaesthesia. 2021;76(5):655–664. doi:10.1111/anae.15317
   PubMed Web of Science ®Google Scholar
• Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007–2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesth Analg. 2014;119(6):1359–1366. doi:10.1213/ANE.0000000000000421
   PubMed Web of Science ®Google Scholar
• Gong X. Malignant hyperthermia when dantrolene is not readily available. BMC Anesthesiol. 2021;21(1):1–11. doi:10.1186/s12871-021-01328-3
   PubMed Web of Science ®Google Scholar
• Xu ZH, Luo AL, Guo XY, et al. Malignant hyperthermia in China. Anesth Analg. 2006;103(4):983–985. doi:10.1213/01.ane.0000237289.66136.cd
   PubMed Web of Science ®Google Scholar
• Li Z, Liu K, Guo X. Dantrolene available in China for malignant hyperthermia treatment. Anesthesiology. 2022;136(3):515–516. doi:10.1097/ALN.0000000000003998
   Web of Science ®Google Scholar
• Yu H, Tan L, Teng Y, et al. The First National Remote Emergency System for Malignant Hyperthermia (MH-NRES) in China: protocol for the design, development, and evaluation of a WeChat applet. JMIR Res Protoc. 2022;11(6):e37084. doi:10.2196/37084
   PubMed Web of Science ®Google Scholar
• Expert Consensus Working Group on the Prevention And Treatment of Malignant Hyperthermia in China. Expert consensus on the prevention and treatment of malignant hyperthermia in China (2020 edition). Chin J Anesthesiol. 2021;41(1):20–25. doi:10.3760/cma.j.cn131073.20210102.00107
   Google Scholar
• Suyama H, Kawamoto M, Yuge O. Prevention and treatment of malignant hyperthermia in certified training hospitals in Japan: a questionnaire. J Anesth. 2002;16(3):207–210. doi:10.1007/s005400200026
   PubMedGoogle Scholar
• Guglielminotti J, Rosenberg H, Li G. Prevalence of malignant hyperthermia diagnosis in obstetric patients in the United States, 2003 to 2014. BMC Anesthesiol. 2020;20(1). doi:10.1186/s12871-020-0934-0
   PubMed Web of Science ®Google Scholar
• Lu Z, Rosenberg H, Li G. Prevalence of malignant hyperthermia diagnosis in hospital discharge records in California, Florida, New York, and Wisconsin. J Clin Anesth. 2017;39:10–14. doi:10.1016/j.jclinane.2017.03.016
   PubMed Web of Science ®Google Scholar
• Urman RD, Rajan N, Belani K, Gayer S, Joshi GP. Malignant hyperthermia-susceptible adult patient and ambulatory surgery center: society for ambulatory anesthesia and ambulatory surgical care committee of the American Society of Anesthesiologists Position Statement. Anesth Analg. 2019;129(2):347–349. doi:10.1213/ANE.0000000000004257
   PubMed Web of Science ®Google Scholar
• Neira VM, Al Madhoun W, Ghaffari K, Barrowman N, Berrigan P, Splinter W. Efficacy of malignant hyperthermia association of the United States-recommended methods of preparation for malignant hyperthermia-susceptible patients using Dräger Zeus anesthesia workstations and associated costs. Anesth Analg. 2019;129(1):74–83. doi:10.1213/ANE.0000000000003441
   PubMed Web of Science ®Google Scholar
• Aderibigbe T, Lang BH, Rosenberg H, Chen Q, Li G. Cost-effectiveness analysis of stocking dantrolene in ambulatory surgery centers for the treatment of malignant hyperthermia. Anesthesiology. 2014;120(6):1333–1338. doi:10.1097/ALN.0000000000000257
   PubMed Web of Science ®Google Scholar
• Belani KG, Cao C, Daugherty D, et al. Malignant hyperthermia status in China: a summary of an international conference. Anesth Analg. 2016;122(2):574–577. doi:10.1213/ANE.0000000000001043
   Google Scholar
• Burkman JM, Posner KL, Domino KB. Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions. Anesthesiology. 2007;106(5):901–906. doi:10.1097/01.anes.0000265148.86566.68
   PubMed Web of Science ®Google Scholar
• Joshi GP, Desai M, Valedon A, Gayer S. Succinylcholine Use and Dantrolene Availability: comment. Anesthesiology. 2019;131(4):934. doi:10.1097/ALN.0000000000002949
   PubMed Web of Science ®Google Scholar
• Larach MG, Klumpner TT, Brandom BW, et al. Succinylcholine use and dantrolene availability: reply. Anesthesiology. 2019;131(4):935–936. doi:10.1097/ALN.0000000000002950
   PubMed Web of Science ®Google Scholar
• Wang YL, Luo AL, Tan G, Cui XL, Guo XY. Clinical features and diagnosis for Chinese cases with malignant hyperthermia: a case cluster from 2005 to 2007. Chin Med J. 2010;123(10):1241–1245. doi:10.3760/cma.j.issn.0366-6999.2010.10.002
   PubMed Web of Science ®Google Scholar
• Kim TW, Singh S, Miller C, et al. Efficacy and cost comparison of case-based learning to simulation-based learning for teaching malignant hyperthermia concepts to anesthesiology residents. J Educ Perioper Med. 2019;21:E631.
   PubMedGoogle Scholar
• Gallegos E, Hennen B. Malignant hyperthermia preparedness training: using cognitive aids and emergency checklists in the perioperative setting. J Perianesthesia Nurs. 2022;37(1):24–28. doi:10.1016/j.jopan.2020.09.020
   PubMed Web of Science ®Google Scholar
• Cain Cindy L, Riess Matthias L, Gettrust L, Jutta N. Malignant hyperthermia crisis: optimizing patient outcomes through simulation and interdisciplinary collaboration. AORN J. 2014;99(2):301–8; quiz309–11. doi:10.1016/j.aorn.2013.06.012
   Web of Science ®Google Scholar